Patent & IP Notice

Last updated: 2025-10-13

.

Patent & Intellectual Property Notice — CellsAI Technologies Inc.

Effective Date: Jule 12, 2025

1. Overview

CellsAI Technologies Inc. (“CellsAI,” “we,” “our,” or “us”) develops proprietary artificial intelligence algorithms, software, and workflows for the analysis of high-content cellular imaging data, with a focus on detection, characterization, and quantitative scoring of senescent cells.

This document outlines the scope of intellectual property (IP) protections, patents, trade secrets, and licensing policies related to our technology, designed to safeguard our innovations and research assets while enabling controlled academic and industrial collaboration.

2. Intellectual Property Ownership

  • All AI algorithms, neural network architectures, software code, analytical pipelines, and documentation developed by CellsAI are the exclusive property of CellsAI Technologies Inc.
  • Any derivative works, improvements, or modifications created in collaboration with R&D partners or contractors remain the property of CellsAI unless otherwise contractually agreed.
  • Users retain full ownership of uploaded research data. CellsAI does not claim any rights to the data submitted by partners or customers.

3. Patents

CellsAI has filed and continues to pursue patent protection for core aspects of our AI-based cellular analysis platform. Key areas covered include:

3.1 AI-Based Senescence Detection

  • Methodology: Automated detection of senescent cells from high-content imaging data using quantitative morphological, cytoplasmic, and nuclear features.
  • Patent Filing: EU-2025-0217 (pending), US Patent Application (pending).
  • Claims Include:
    • Feature extraction algorithms for nuclear shape, granularity, and texture.
    • Integration of multiple fluorescent channels into a composite senescence score.
    • Batch normalization methods for cross-experiment standardization.

3.2 Compound Scoring & Ranking System

  • Methodology: Scoring and ranking of chemical compounds or biological perturbagens based on AI-predicted cellular phenotypes.
  • Patent Filing: EU-2025-0218 (pending), US Patent Application (pending).
  • Claims Include:
    • Multi-metric scoring algorithms combining morphological, spatial, and temporal features.
    • Statistical ranking of compound effects on senescence.
    • Visual report generation with feature prioritization.

3.3 Transfer Learning and Model Adaptation

  • Methodology: Transfer learning pipelines enabling adaptation of baseline models to custom laboratory datasets.
  • Patent Filing: EU-2025-0219 (pending), US Patent Application (pending).
  • Claims Include:
    • Automated feature alignment between public datasets (e.g., JUMP-CP, BBBC047) and proprietary lab datasets.
    • Model fine-tuning with minimal labeled data while preserving generalization.

3.4 Data Integration & Explainability

  • Methodology: Integration of morphological features into interpretable AI reports for research validation.
  • Patent Filing: EU-2025-0220 (pending), US Patent Application (pending).
  • Claims Include:
    • Generation of interpretable morpho-feature maps.
    • Probabilistic scoring and confidence metrics for senescence prediction.
    • Integration with laboratory LIMS and HCS pipelines.

4. Licensing & Usage

  • Users and partners are granted a limited, non-exclusive, non-transferable license to access and use CellsAI software, models, and IP for internal research purposes only.
  • Commercial use, sublicensing, or redistribution requires prior written consent from CellsAI Technologies Inc.
  • Unauthorized reproduction, reverse engineering, or distribution of proprietary code, models, or workflows is strictly prohibited and subject to legal enforcement.

5. Trade Secrets

  • Source code, model weights, neural network architectures, proprietary preprocessing pipelines, and analysis workflows constitute CellsAI trade secrets.
  • Access to trade secrets is restricted to employees, contractors, and partners under executed confidentiality agreements.
  • Disclosure of trade secrets or proprietary methods without authorization is strictly prohibited and enforceable under U.S. and international trade secret laws.

6. Collaboration and Partner IP

  • Collaborative R&D agreements, including work with CellsAI Europe B.V., include clear definitions of IP ownership and licensing.
  • Any new IP jointly developed during collaborations is governed by mutually agreed terms in contracts and NDAs.
  • CellsAI retains the right to license improvements and derivative works while respecting partner contributions.

7. IP Enforcement

  • CellsAI actively monitors and enforces its intellectual property rights worldwide.
  • Violations, including unauthorized copying, reverse engineering, or commercial exploitation, may result in civil or criminal actions in applicable jurisdictions.
  • Patent applications are filed and maintained in the U.S., EU, and selected international jurisdictions to protect proprietary technology globally.

8. Contact

For inquiries related to intellectual property, patents, licensing, or collaborations:

CellsAI Technologies Inc.
651 Forest Ave, Palo Alto, CA 94301, USA
Email: aimedcells@gmail.com